Gritstone bio, Inc. (GRTS) is a cutting-edge biotechnology company focused on cancer immunotherapy. The company is pioneering a new class of cancer immunotherapies to combat multiple cancer types through its unique artificial intelligence (AI)-powered platform referred to as Gritstone EDGE™. The California-based company is publicly traded on NASDAQ under the ticker symbol GRTS.
Gritstone bio was founded in August 2015 with the objective of eradicating cancer by developing transformative and curative therapies. The firm primarily operates in the cancer therapeutics area developing antibodies, vaccines, and other kinds of drugs. Most of these drugs are still in the clinical trial stages, under investigation for their efficacy in treating various types of cancer. The company's lead product candidate, GRANITE, uses patient-specific neoantigens to deploy a broad-spectrum anti-tumor response, while its off-the-shelf vaccine, SLATE, uses shared neoantigens to treat select tumor types.
The company's EDGE series explores the unique mutated proteins that are manufactured by cancer cells and not healthy cells, and are therefore ideal targets for its cancer immunotherapies. By creating software that can precisely predict these antigens, Gritstone bio has streamlined a process that has the potential to change cancer treatment dramatically.
In addition to its primary cancer fighting roadmap, Gritstone bio has also utilized its technology platform in response to the COVID-19 pandemic. In collaboration with the Bill & Melinda Gates Foundation, Gritstone bio has developed a second-generation vaccine candidate for COVID-19 which aims to address the problems posed by rapidly mutating viral strains.
The success of Gritstone bio, Inc. is significantly rooted in its approach to combine significant biological insight with big data analytics and AI to create an entirely new class of therapeutics. The company’s culture of rigorous experimental analysis and clinical development is evident in the advanced and diverse pipeline of drugs for cancer treatment.
Gritstone bio has gradually established itself in the biotechnology industry, making significant strides in leveraging innovative technology to bring new possibilities to the future of cancer treatment. The continuous quest to revolutionize cancer therapies, its involvement in COVID-19 vaccine development, and its unique and pioneering approach have positioned Gritstone bio, Inc. (GRTS) as a key player in the biotech industry.